Is Globus Medical, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Globus Medical, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, particularly given its P/E ratio of 36, which is significantly higher than the peer average of 18.37 for comparable companies. Additionally, the EV to EBITDA ratio stands at 13.54, while peers like Lantheus Holdings, Inc. show a much lower ratio of 7.12, further suggesting that Globus Medical is priced at a premium compared to its industry counterparts.
In comparison to its peers, Globus Medical's PEG ratio of 0.54 indicates potential growth, but this is overshadowed by its relatively high valuation ratios. Notably, Masimo Corp. has a P/E ratio of 179.74, while Merit Medical Systems, Inc. is at 42.46, both of which are higher than Globus Medical's P/E. The company's stock has underperformed against the S&P 500, with a year-to-date return of -26.01% compared to the S&P 500's 16.30%, reinforcing the notion that it may be overvalued in the current market context.